Skip to main content

Table 1 Distribution of main asthma comorbidities in the PROXIMA study population

From: Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis

ComorbidityN = 123
Number of patients with at least one comorbidity77 (62.6%)
Allergic bronchopulmonary aspergillosis2 (1.6%)
Atopic dermatitis3 (2.4%)
Bronchiectasis3 (2.4%)
Cardiovascular disease26 (21.1%)
Chronic obstructive pulmonary disease4 (3.3%)
Chronic rhinitis17 (13.8%)
Chronic rhinosinusitis without nasal polyps (CRSsNP)22 (17.9%)
Chronic rhinosinusitis with nasal polyps (CRSwNP)17 (13.8%)
Chronic spontaneous urticaria1 (0.8%)
Chronic/recurrent respiratory infections2 (1.6%)
Gastroesophageal reflux16 (13.0%)
Hormonal disturbances16 (13.0%)
Obesity5 (4.1%)
Obstructive sleep apnea/sleep-disordered breathing3 (2.4%)
Psychologic disease (anxiety, depression, behavioral disorders)6 (4.9%)
Other19 (15.4%)